CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Talca, Chile

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • Invisalign® System with Mandibular Advancement

    Phase

    N/A

    Span

    151 weeks

    Sponsor

    Align Technology, Inc.

    Brampton, Ontario

    Recruiting

  • AZD0486 as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

    This is a modular, Phase II, multicenter, single-arm, open-label study to evaluate the efficacy and safety of AZD0486 monotherapy administered as an intravenous (IV) infusion in participants with relapsed or refractory B-NHL. The purpose of this study is to determine the efficacy and safety of AZD0486 administered at the RP2D in adults 18 to 80 years of age with relapsed or refractory B-NHL.

    Phase

    2

    Span

    238 weeks

    Sponsor

    AstraZeneca

    Brampton, Ontario

    Recruiting

  • Autologous Hair Follicle Derived Secretome as Adjunct to Aesthetic Procedures

    This non-interventional, observation study is to collect real-world data on the use of an autologous, hair follicle derived secretome topical cosmetic product following various medical aesthetic procedures.

    Phase

    N/A

    Span

    25 weeks

    Sponsor

    Acorn Biolabs Inc.

    Brampton, Ontario

    Recruiting

  • A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a)

    Phase

    3

    Span

    265 weeks

    Sponsor

    Eli Lilly and Company

    Brampton, Ontario

    Recruiting

  • VOICE-Early Response to Vedolizumab and IL-23 Antagonists in Participants With Crohn's Disease: A Prospective Observational Study

    Vedolizumab (VDZ), a monoclonal antibody that selectively targets intestinal T-cell trafficking, is an effective and safe treatment for moderately to severely active Crohn's disease (CD). Recent evidence from open-label, blinded endpoint studies such as VERSIFY and LOVE-CD provide further support for the efficacy of VDZ in achieving clinical, endoscopic, histologic and radiologic disease improvement in CD. Despite these data, VDZ is generally perceived to have a slower onset of action than other biologics, including tumor necrosis factor (TNF) antagonists and the interleukin (IL)-12/23 antagonist, ustekinumab (UST). The IL-23 antagonist risankizumab (RISA) has been more recently approved for treatment of CD and post-hoc analyses of SEQUENCE trial data showed RISA to be superior to UST for inducing clinical remission at Week 24, and thus, RISA may also be considered to have a quicker onset of action than VDZ. This perception largely emanates from the results of the VDZ pivotal for CD (GEMINI 2) where efficacy was assessed at Week 6 after only 2 doses in a largely refractory population. However, in clinical practice VDZ induction consists of 3 doses of VDZ 300 mg administered intravenously at weeks 0, 2 and 6 instead of the 2 doses used in the pivotal trials. In recent clinical trials, induction endpoints for therapeutics in CD are now typically measured at least after Week 12. Accordingly, it is uncertain whether the generally held perception of a relatively slow onset of action for VDZ is accurate. Moreover, it should also be noted that the perception of a slow onset of action has also been conflated to infer that VDZ is a relatively less effective induction therapy in CD than TNF antagonists or UST. Further data to evaluate these issues are needed. Rapidity of symptom resolution, which is commonly used as a surrogate for speed of onset, is a priority for patients and clinicians. It is therefore important to better understand the kinetics of symptom improvement captured using patient-reported outcomes (PROs) in patients initiating VDZ for treatment of CD.

    Phase

    N/A

    Span

    146 weeks

    Sponsor

    Alimentiv Inc.

    Brampton, Ontario

    Recruiting

  • A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants ≥ 18 Years of Age With Asthma

    Phase

    3

    Span

    69 weeks

    Sponsor

    GlaxoSmithKline

    Brampton, Ontario

    Recruiting

  • Study of JK07 in Patients With Chronic Heart Failure

    Phase

    2

    Span

    118 weeks

    Sponsor

    Salubris Biotherapeutics Inc

    Brampton, Ontario

    Recruiting

  • Phase 3 Study of Plozasiran in Adults With Hypertriglyceridemia

    Phase

    3

    Span

    128 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Brampton, Ontario

    Recruiting

  • Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia

    Phase

    3

    Span

    119 weeks

    Sponsor

    Arrowhead Pharmaceuticals

    Brampton, Ontario

    Recruiting

  • ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack

    Phase

    3

    Span

    115 weeks

    Sponsor

    Novo Nordisk A/S

    Brampton, Ontario

    Recruiting

1-10 of 66
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information